Oncolytis Biotech shares are trading lower after the company announced that it entered into an agreement with Leede Jones Gable as an underwriter and bookrunner to purchase, on a brought-deal basis, 6.667 million units for gross proceeds of $15 million at $2.25 per unit.
Portfolio Pulse from Benzinga Newsdesk
Oncolytis Biotech has entered into an agreement with Leede Jones Gable to purchase 6.667 million units for gross proceeds of $15 million. This has led to a decrease in the company's share price.
July 31, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oncolytis Biotech's shares are trading lower after the company announced a deal with Leede Jones Gable.
The announcement of the deal with Leede Jones Gable has led to a decrease in Oncolytis Biotech's share price. This is likely due to the dilution of shares as a result of the deal, which often leads to a decrease in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100